摘要
目的:利用网织红细胞血红蛋白含量(CHr)监测终末期肾病(ESRD)缺铁性贫血患者应用促红细胞生成素及补铁治疗中的临床意义。方法:选择临床确诊ESRD的血液透析患者常规使用人重组促红细胞生成素(rHuEPO)治疗贫血,分别以CHr和铁蛋白(SF)及转铁蛋白饱和度(TSAT)作为铁缺乏指标指导常规补铁,比较两组间的疗效;并观察两组患者在补铁治疗前后CHr和常规血液学指标的变化。结果:(1)CHr组与铁蛋白组实际疗效差异无统计学意义,但前者使用的铁剂剂量小于后者(526.36±37.87比583.52±30.86,P<0.05);(2)CHr在补铁治疗后第4天就可看出显著效果(P<0.01),而其他指标要1月到2月才显现。结论:CHr作为铁缺乏指标能及时发现功能性缺铁,在指导ESRD透析患者的补铁治疗时较传统方法更安全、稳定,是铁剂治疗效果早期评估的快速有效指标。
Objective：To investigate the clinical significance of reticulocyte hemoglobin content （CHr） ,monitoring the ther- apy effect with erythropoietin and iron supplement in the end - stage renal disease patients with iron deficiency anemia. Results： Methods： The diagnosed ESRD hemodialysis patients were treated with restructuring erythropoietin （rHuEPO） as clinical convention- al treatment of anemia, who were conventional supplemented iron in the guide of CHr and iron protein （SF） and transfer in saturation （TSAT） as an lack of iron index respectively. Curative effect was compared between the two groups, and then CHr and conventional hematology index changes were observed after treatment with iron supplement. Results： （ 1 ） There was no significant differences in treatment between the group of CHr and iron protein （526.36±37.87vs 583.52±30.86,P 〈0.05）, but the former using iron sup- plement was less than the latter dose. （2） CHr was appeared notable effect after 4 days with iron supplement. However the other inde- xes were showed after one or two months. Conclusion： Chr could prompt functional iron deficiency timely as a lack of Iron index, and was more secure, stable than the traditional methods in the guide of therapy of supplement iron in the ESRD hemodialysis patients. Thus Chr was a rapid and effective index in the early evaluation of treatment effect with iron supplement.
出处
《中国中西医结合肾病杂志》
2013年第1期45-47,共3页
Chinese Journal of Integrated Traditional and Western Nephrology
基金
浙江省医学高等专科学校自然基金资助项目(N0.2010B006)
关键词
网织红细胞血红蛋白含量
促红细胞生成素
Reticulocyte hemoglobin content （CHr） Renal anemia Erythropoietin （EPO）
